Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
Status:
Completed
Trial end date:
2018-10-24
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of decitabine when given
together with filgrastim, cladribine, cytarabine, and mitoxantrone hydrochloride in treating
patients with acute myeloid leukemia or myelodysplastic syndrome that is newly diagnosed, has
come back or has not responded to treatment. Drugs used in chemotherapy, such as decitabine,
cladribine, cytarabine, and mitoxantrone hydrochloride work in different ways to stop the
growth of cancer cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Colony-stimulating factors, such as filgrastim, may increase
the production of blood cells and may help the immune system recover from the side effects of
chemotherapy. Decitabine, filgrastim, cladribine, cytarabine, and mitoxantrone hydrochloride
may work better in treating patients with acute myeloid leukemia and myelodysplastic
syndrome.